II. Epidemiology
- Under-Vaccination despite high efficacy and potential to prevent anogenital and oropharyngeal cancer
- Girls: 57.3% vaccinated (as of 2013 in U.S.)
- Boys: 34.6% vaccinated (as of 2013 in U.S.)
III. Indications
-
General indications
- Prevention of Cervical Dysplasia
- Prevention of anal cancer (receptive anal intercourse)
- Girls and women: Part of Primary Series
- Females routinely at age 11-12 and catch-up age <26 years
- Vaccination may start as early as age 9 years
- Boys and men
- Part of Primary Series in United States as of 2012
- Males routinely at age 11 to 12 years and catch-up age 21 years
- Routine use in males ages 22 to 26 years old who have HIV Infection or who have sex with men
- Permissive use of Vaccine in males ages 22 to 26 years old
- Reduces risk of Genital Warts, precancerous lesions and transmission to sexual partners
IV. Preparations: Gardasil-9
- Released in 2015 with additional coverage for 5 HPV antigens in addition to the 4 in the original Gardasil
- Replaces original Gardasil Vaccine
- Approved for males and females 9 to 26 years old
- Improves coverage against Cervical Cancer causing HPV from 70% with Gardasil to 90% with Gardasil-9
- Gardasil-9 also reduces the risk of vulvar, vaginal and anal cancers when compared with Gardasil
- Gardasil-9 causes more local reactions than Gardasil (in which local reactions were already very common)
- Two low risk HPV types (but cause 90% of Genital Warts)
- HPV 6
- HPV 11
- Two high risk HPV types (cause 70% of Cervical Cancers)
- HPV 16
- HPV 18
- Additional HPV types responsible for cervical, vulvar, vaginal and anal cancers (added to Gardasil-9)
- HPV 31
- HPV 33
- HPV 45
- HPV 52
- HPV 58
V. Preparations: Gardasil (original version)
- No longer available in U.S., was replaced by Gardasil-9 as of 2015
- Mixture of primary capsid proteins of 4 HPV types (Quadrivalent)
- Two low risk HPV types (but cause 90% of Genital Warts)
- HPV 6
- HPV 11
- Two high risk HPV types (cause 70% of Cervical Cancers)
- HPV 16
- HPV 18
VI. Preparations: Cervarix
- Human Papillomavirus Bivalent Vaccine
- Not available in United States
- Approved only for girls and women ages 9 to 25 years old
- Covers only two high risk types and none related to Genital Warts (contrast with Gardasil)
- HPV 16
- HPV 18
VII. Contraindications
- Pregnancy
- Anaphylaxis to yeast
VIII. Adverse Effects
IX. Efficacy
- Highest efficacy when administered prior to onset of sexual activity (prior to exposure)
X. Dosing
- Intramuscular Injection
- Two dose schedule as of 2017 (indicated if started before age 15 years and immunocompetent)
- Schedule: Two doses at 6-12 months apart
- Indicated for ages 9-14 years old (those >15 years old should use 3 dose schedules)
- First 2 doses must be at least 5 months apart (otherwise use 3 dose schedule)
- (2016) Presc Lett 23(12): 67
- Three dose schedule (age of first dose >15 years old or immunocompromised)
- Schedule: 0, 2, and 6 months
- If one dose given before age 15 years old, may give a single booster dose age 15-26 years old
XI. Cost
- Three doses: >$1000 for Gardasil-9 (covered by most U.S. insurance plans)
- Original Gardasil was priced at >$400 for three doses
XII. Resources
XIII. References
- Goeser (2007) Am Fam Physician 76:573-4
- Joura (2015) N Engl J Med 372:711-23 [PubMed]
- Rerucha (2018) Am Fam Physician 97(7): 441-8 [PubMed]
- Villa (2005) Lancet Oncol 6:271-8 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies (from Trip Database) Open in New Window
| Definition (HL7V3.0) | <p>human papilloma virus vaccine</p> |
| Definition (NCI_NCI-GLOSS) | A vaccine used to prevent genital warts, cervical cancer, vulvar cancer, and vaginal cancer caused by certain types of human papillomavirus (HPV). It is also used to prevent lesions that are caused by those viruses and that can lead to cervical, vulvar, or vaginal cancer. |
| Definition (NCI) | A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation. |
| Concepts | Immunologic Factor (T129) , Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
| MSH | D053918 |
| SnomedCT | 424519000, 423929007 |
| HL7 | 62 |
| English | HPV Vaccines, Human Papilloma Virus Vaccines, Human Papillomavirus Vaccines, Papillomavirus Vaccines, Human, Vaccines, Human Papillomavirus, human papillomavirus vaccine, Human papillomavirus vaccine (product), Human papillomavirus vaccine, Human papillomavirus vaccine (substance), HPV vaccine, human papilloma virus vaccine (medication), human papilloma virus vaccine, HPV, Recombinant Human Papilloma Virus Vaccine, HPV Vaccine, Human Papilloma Virus Vaccine |
| German | Humanes Papillomavirus-Impfstoffe, HPV-Vakzine, HPV-Impfstoffe, Humanes Papillomavirus-Vakzine |
| French | Vaccins anti-HPV, Vaccins anti-papillomavirus humain, Vaccins antipapillomavirus humain |
| Spanish | vacuna anti-papilomavirus humano, vacuna anti-papilomavirus humano (producto), vacuna anti-papilomavirus humano (sustancia), Vacunas contra el Papillomavirus Humano, vacuna anti-HPV, vacuna contra virus del papiloma humano, vacuna contra HPV |
| Czech | lidský papilomavirus - vakcíny, HPV vakcíny |
| Portuguese | Vacinas contra Papilomavírus Humano |
| Italian | Vaccini contro il Papillomavirus umano, Vaccini contro il papilloma virus umano, Vaccini anti HPV |
Ontology: Gardasil (C1721787)
| Concepts | Pharmacologic Substance (T121) , Immunologic Factor (T129) |
| MSH | C512720 |
| English | Merck brand of HPV quadrivalent vaccine, Gardasil |
